StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

Stock analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright decreased their price objective on DBV Technologies from $10.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th.

DBV Technologies Price Performance

DBVT opened at $0.62 on Wednesday. The business has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $0.80. The company has a market cap of $119.58 million, a PE ratio of -1.48 and a beta of 0.73. DBV Technologies has a 52 week low of $0.42 and a 52 week high of $2.26.

DBV Technologies’s stock is scheduled to reverse split before the market opens on Monday, June 3rd. The 1-2 reverse split was announced on Monday, June 3rd. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 3rd.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, March 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.10. The business had revenue of $8.88 million during the quarter, compared to the consensus estimate of $1.10 million. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. During the same period in the prior year, the business posted ($0.23) EPS. As a group, sell-side analysts expect that DBV Technologies will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cowen AND Company LLC bought a new position in shares of DBV Technologies in the fourth quarter valued at $49,000. Landscape Capital Management L.L.C. bought a new position in shares of DBV Technologies in the third quarter valued at $94,000. Optiver Holding B.V. increased its holdings in shares of DBV Technologies by 595.2% in the third quarter. Optiver Holding B.V. now owns 274,874 shares of the company’s stock valued at $374,000 after buying an additional 235,337 shares in the last quarter. Finally, Yiheng Capital Management L.P. increased its holdings in shares of DBV Technologies by 6.2% in the first quarter. Yiheng Capital Management L.P. now owns 5,568,909 shares of the company’s stock valued at $4,172,000 after buying an additional 327,345 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors and hedge funds.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.